Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.

被引：4

作者：

Dent, R. A.

Lindeman, G. J.

Clemons, M.

Wildiers, H.

Chan, A.

McCarthy, N. J.

Singer, C. F.

Lowe, E. S.

Kemsley, K.

Carmichael, J.

机构：

[1] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada

[2] Royal Melbourne Hosp, Parkville, Vic 3050, Australia

[3] Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia

[4] Ottawa Hosp, Ctr Canc, Ottawa, ON, Canada

[5] Katholieke Univ Leuven Hosp, Leuven Canc Inst, Louvain, Belgium

[6] Mt Hosp, Perth, WA, Australia

[7] Wesley Med Ctr Brisbane, Auchenflower, Australia

[8] Med Univ Vienna, Gen Hosp, Vienna, Austria

[9] AstraZeneca, Wilmington, DE USA

[10] AstraZeneca, Macclesfield, Cheshire, England

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.1018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1018

引用

页数：1